Drug treatment of non-motor symptoms in Parkinson's disease

Expert Opinion on Pharmacotherapy
Thomas Müller

Abstract

Non-motor symptoms may considerably reduce parkinsonian quality of life, particularly in advanced stages of the disease. Autonomic features, such as seborrhoea, hyperhidrosis, orthostatic hypotension, excessive salivation, bladder dysfunction and GI disturbances, and neuropsychiatric symptoms, such as depression, sleep disorders, psychosis and dementia, appear in the course of Parkinson's disease. Pharmacotherapy of these non-motor symptoms complicates long-term antiparkinsonian combination drug therapy due to possible drug interactions, side effects and changes in metabolism. Moreover, antiparkinsonian compounds themselves contribute to the onset of these non-motor symptoms to a considerable extent. This complicates differentiation between the disease process itself and drug-related effects, thus influencing therapeutic options, which are often limited because of comorbidity and polypharmacy. Therefore, standardised recommendations are questionable, since drug tolerability and response differ between patients. Nevertheless, this review tries to provide a survey of possible therapeutic options for the treatment of the symptoms of Parkinson's disease other the dopamine-sensitive motor features.

References

Jan 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·S A Factor, D Brown
Aug 1, 1991·Neurology·D B Boivin, J Montplaisir
Oct 1, 1990·Clinical Neuropharmacology·W C KollerD Parrish
Jan 1, 1994·The Journal of Neuropsychiatry and Clinical Neurosciences·M A Menza, M H Mark
Oct 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·F IshizakiS Nakamura
Apr 1, 1993·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·M De MarinisA Agnoli
Jan 1, 1993·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·R Freeman, E Miyawaki
Oct 1, 1995·Journal of Geriatric Psychiatry and Neurology·R J LeoL A Hershey
Jan 1, 1994·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·T BüttnerH Przuntek
Feb 1, 1995·Clinical Neuropharmacology·A P SempereF Coria
Jul 1, 1996·Journal of Neurology·M PondalF Bermejo
Sep 1, 1996·Seminars in Neurology·E M Quigley
Apr 26, 1997·Lancet·A DanieleP Bartolomeo
Jul 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·A M BonnetY Agid
Dec 17, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·I SoykanR W McCallum
Dec 24, 1997·Acta Neurologica Scandinavica·T MüllerH Przuntek
Apr 1, 1998·Neurology·J L Goren, J H Friedman
Apr 4, 1998·Orthopaedic Nursing·M Segatore
Jun 3, 1998·The Journal of Neuropsychiatry and Clinical Neurosciences·C MoellentineT Pileggi
Jun 5, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·R M TroschW C Koller
Mar 11, 1999·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Dec 10, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·W H Jost
Jan 14, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S A FactorE S Molho
Jan 15, 2000·Neurology·P K PalJ K Tsui
Apr 6, 2000·Neurology·W J WeinerL M Shulman
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·A M KuopioU K Rinne
Apr 25, 2000·Lancet·J J FerreiraO Rascol
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·A D SiderowfM B Stern
Jul 25, 2000·Journal of Neural Transmission·P A Fall, A K Granérus
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S J FruchtS Fahn
Aug 19, 2000·Lancet·W Pirker, S Happe
Aug 24, 2000·The Journal of Neuropsychiatry and Clinical Neurosciences·T EllisJ H Growdon

❮ Previous
Next ❯

Citations

Dec 6, 2012·Translational Neurodegeneration·Thomas Müller
Feb 28, 2013·The Journal of Dermatology·Burcu AltunrendeNebil Yildiz
Nov 8, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Ning ZhangYingdong Zhang
Mar 31, 2010·Criminal Behaviour and Mental Health : CBMH·Kerry SheldonGita Patel
Aug 18, 2012·Arquivos de neuro-psiquiatria·Flavio Henrique de Rezende CostaMaurice Borges Vincent
Nov 28, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·E CuboM Aguilar
Aug 15, 2021·Drug Metabolism and Personalized Therapy·Taiwo G Olubodun-ObadunOlufunmilayo O Adeyemi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Drug Metabolism & Toxicology
Thomas Müller
Journal of Geriatric Psychiatry and Neurology
Roseanne D DobkinMargery H Mark
© 2022 Meta ULC. All rights reserved